“Transformando Vidas: A Chegada do Tratamento Inovador para a Síndrome de WHIM”

Referências

1. Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, Gorelick KJ, Ebrahim T, Garg V, Tang W, Jiang H, Skerlj R, Beaussant Cohen S. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020 Dec 24;136(26):2994-3003. doi: 10.1182/blood.2020007197.

2.  Food and drug administration. FDA approves first drug for WHIM syndrome, a rare disorder that can lead to recurrent, life-threatening infections. Disponível em: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections. Acessado em 13.05.2

3. HEUSINKVELD, Lauren E. et al. WHIM syndrome: from pathogenesis towards personalized medicine and cure. Journal of clinical immunology, v. 39, p. 532-556, 2019.

4. McDermott DH, Murphy PM. WHIM syndrome: Immunopathogenesis, treatment and cure strategies. Immunol Rev. 2019 Jan;287(1):91-102. doi: 10.1111/imr.12719.